WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2010026565) PKCeta AS A MARKER FOR CANCER PROGNOSIS AND TREATMENT
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2010/026565    International Application No.:    PCT/IL2009/000828
Publication Date: 11.03.2010 International Filing Date: 27.08.2009
IPC:
C12Q 1/52 (2006.01)
Applicants: BEN GURION UNIVERSITY OF THE NEGEV RESEARCH AND DEVELOPMENT AUTHORITY [IL/IL]; P.O. Box 653 84105 Beer Sheva (IL) (For All Designated States Except US).
LIVNEH, Etta [IL/IL]; (IL) (For US Only).
KARP, Galia [IL/IL]; (IL) (For US Only)
Inventors: LIVNEH, Etta; (IL).
KARP, Galia; (IL)
Agent: WOLFF BREGMAN AND GOLLER; P.O. Box 1352, Jerusalem 9113 (IL)
Priority Data:
61/136,382 02.09.2008 US
Title (EN) PKCeta AS A MARKER FOR CANCER PROGNOSIS AND TREATMENT
(FR) PKCETA COMME MARQUEUR POUR LE PRONOSTIC ET LE TRAITEMENT DU CANCER
Abstract: front page image
(EN)This invention provides a method and kit for the assessment of prognosis of a subject having or suspected of having caner, by determination of the cellular localization of PKCη. This invention further describes a method for the determination of a subject's responsiveness to a chemotherapeutic regimen, wherein little or no change of cellular localization of PKCη to be cytoplasmic, following chemotherapy treatment is indicative of a lack of responsiveness to the chemotherapeutic regimen. This invention further provides treatment methods for invasive breast or lung cancer via the administration of an agent, which inhibits PKCη translocation to membranous compartments of the cell.
(FR)La présente invention concerne une méthode et un kit destinés à l'évaluation du pronostic d'un sujet ayant un cancer ou suspecté d'avoir un cancer, par la détermination de la localisation cellulaire du PKCη. L’invention concerne en outre une méthode de détermination de la réaction d'un sujet à un régime chimiothérapique, un faible changement voire aucun changement dans la localisation cellulaire du PKCη, en direction du cytoplasme, à la suite du traitement chimiothérapique, étant un indicateur d’un manque de réaction au régime chimiothérapique. Cette invention concerne de plus des méthodes de traitement de cancers invasifs du sein ou des poumons par le biais de l'administration d'un agent, qui inhibe la translocation des PKCη vers des compartiments membranaires de la cellule.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)